Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12079109 | 0.79 | NAMPT (0.77) | NAMPTALDH1A1CXCR4KMT2AMEN1 | |
| SCHEMBL1078768 | 0.78 | NAMPT (1.00) | NAMPTKMT2AMEN1SLC2A1 | |
| SCHEMBL7970997 | 0.76 | CXCR4 (0.69) | NAMPTALDH1A1CXCR4KMT2AMEN1 | |
| SCHEMBL1079531 | 0.75 | NAMPT (0.67) | NAMPTALDH1A1CXCR4SLC2A1MAPT | |
| SCHEMBL12078587 | 0.75 | NAMPT (0.88) | NAMPTALDH1A1KMT2AMEN1SLC2A1 | |
| SCHEMBL12077395 | 0.75 | NAMPT (0.88) | NAMPTALDH1A1KMT2AMEN1SLC2A1 | |
| SCHEMBL996398 | 0.74 | KEAP1 (0.71) | NAMPTALDH1A1CXCR4KMT2AMAPT | |
| SCHEMBL12793433 | 0.74 | NAMPT (0.72) | NAMPTALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL19358860 | 0.73 | CXCR4 (0.82) | NAMPTALDH1A1CXCR4MAPTLMNA | |
| SCHEMBL30254760 | 0.73 | CXCR4 (0.78) | ALDH1A1CXCR4MAPTLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079859-B2 | Synthetic lethal targeting of glucose transport | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-14 | — | — | US | claimed |
| EP-2456435-B1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | UNIV LELAND STANFORD JUNIOR (US) | 2015-06-24 | — | — | EP | claimed |
| US-20140128397-A1 | SYNTHETIC LETHAL TARGETING OF GLUCOSE TRANSPORT | RUGA CORPORATION | 2014-05-08 | — | — | US | claimed |
| US-20120225862-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | AUCKLAND UNIVSERVICES LIMITED (NZ) | 2012-09-06 | — | — | US | claimed |
| EP-2456435-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | The Board of Trustees of The Leland Stanford Junior University (US) | 2012-05-30 | — | — | EP | claimed |
| WO-2011011514-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-01-27 | — | — | WO | claimed |
| US-9079859-B2 | Synthetic lethal targeting of glucose transport | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-14 | — | — | US | disclosed |
| EP-2456435-B1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | UNIV LELAND STANFORD JUNIOR (US) | 2015-06-24 | — | — | EP | disclosed |
| EP-2456435-B1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | UNIV LELAND STANFORD JUNIOR (US) | 2015-06-24 | — | — | EP | disclosed |
| US-20140228363-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20140128397-A1 | SYNTHETIC LETHAL TARGETING OF GLUCOSE TRANSPORT | RUGA CORPORATION | 2014-05-08 | — | — | US | disclosed |
| EP-2681195-A1 | NOVEL KINASE INHIBITORS | Novartis AG (CH) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012120428-A1 | NOVEL KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-13 | — | — | WO | disclosed |
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225862-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | AUCKLAND UNIVSERVICES LIMITED (NZ) | 2012-09-06 | — | — | US | disclosed |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| EP-2456435-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | The Board of Trustees of The Leland Stanford Junior University (US) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011011514-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | PIM1, PIM2, PIM3 | NAMPT 2601/4885ALDH1A1 1758/4885CXCR4 1822/4885 |
| US-20120225862-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | BRDT, NISCH, PAICS | NAMPT 624/4885ALDH1A1 1336/4885CXCR4 3954/4885 |
| US-20140228363-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | NAMPT 2105/4885ALDH1A1 2104/4885CXCR4 2069/4885 |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | NAMPT 2105/4885ALDH1A1 2104/4885CXCR4 2069/4885 |
| US-20140128397-A1 | SYNTHETIC LETHAL TARGETING OF GLUCOSE TRANSPORT | SLC2A1, SLC2A3, SLC2A2 | NAMPT 601/4885ALDH1A1 2161/4885CXCR4 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.